IMCR — Immunocore Holdings plc

Summary of Immunocore (IMCR) Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• KIMMTRAK Revenue: Generated $192 million in the first half of 2025, a 32% year-over-year increase. Q2 revenue was $98 million, reflecting a 30% increase year-over-year and a 4% sequential increase from Q1.
• U.S. Performance: Q2 U.S. net revenue was $64 million, a 15% increase compared to Q2 2024, with a duration of therapy averaging 13 months and market penetration at 68%.
• European Performance: Q2 European revenue was $33 million, marking a 115% year-over-year growth, driven by successful launches in the U.K., Poland, and the Netherlands.
• Net Loss: Decreased from $36 million in the first half of 2024 to $5 million in the same period of 2025.
• Cash Position: As of June 30, 2025, the company had $883 million in cash and marketable securities.

2. Strategic Updates and Business Highlights

• Global Expansion: KIMMTRAK is now launched in 28 countries and approved in 39, with a focus on expanding access in Turkey and the MENA region through a new partnership.
• Clinical Trials: Progressing in three Phase III trials for melanoma, with TEBE-AM expected to complete enrollment within the next 12 months. The ATOM study is in early activation stages.
• Pipeline Development: Plans to file a Clinical Trial Application (CTA) for autoimmune candidates in type 1 diabetes by year-end 2025, with trials expected to start in 2026.

3. Forward Guidance and Outlook

• KIMMTRAK Growth: Anticipated to continue growing modestly, with expectations for incremental growth in Europe as recent launches mature.
• R&D Investment: Continued investment in R&D is expected to increase operating expenses, with a focus on advancing clinical trials and early-stage programs.
• Future Revenue: The company expects to pay approximately $65 million related to European rebate accruals from prior periods in the second half of 2025.

4. Bad News, Challenges, or Points of Concern

• Moderating Growth: Growth from KIMMTRAK is expected to moderate as the product enters its fourth year on the market.
• Pricing Negotiations: Previous revenue reserves due to pricing negotiations in Europe could impact future revenue stability.
• Regulatory Risks: Concerns regarding potential shifts in FDA approval processes for oncology drugs, especially in light of recent industry developments, were highlighted.

5. Notable Q&A Insights

• Duration of Therapy: The average duration of therapy for KIMMTRAK is currently at 13 months, with ongoing discussions about its potential to extend further.
• FDA Engagement: The company has engaged with the FDA regarding trial designs, maintaining confidence in the TEBE-AM and ATOM trials' compliance with regulatory expectations.
• Competitive Landscape: KIMMTRAK is positioned as the standard of care in uveal melanoma, with ongoing monitoring of emerging competitors in the space.
• International Revenue Variability: The company noted variability in international revenues, which is typical and expected to stabilize with further product launches.

In conclusion, Immunocore reported strong financial results for Q2 2025, driven by KIMMTRAK's robust sales performance and strategic expansion efforts. However, the company faces challenges related to moderating growth and regulatory scrutiny, which will require careful navigation as it advances its pipeline and maintains market leadership.